Navigation Links
Keystone Dental to Pay Nobel Biocare $2 Million to Settle Unfair Competition, Trade Secret Violations, and Tortious Interference Lawsuit
Date:9/3/2008

YORBA LINDA, Calif., Sept. 3 /PRNewswire/ -- Nobel Biocare announced today it has reached a favorable settlement of a lawsuit brought against Keystone Dental, Inc., a dental implant company funded by the multi-billion dollar private equity firm Warburg Pincus, in the Superior Court of Connecticut. The settlement terms provide for Keystone Dental to pay $2 million to Nobel Biocare and that Keystone Dental not hire or solicit any current Nobel Biocare employee through February 1, 2009. Keystone Dental is also required to arrange for the collection and destruction of Nobel Biocare confidential and proprietary information in its or its employees' possession and represent that its employees will not use or disclose any marketing or sales materials licensed by and obtained from Nobel Biocare.

"Nobel Biocare stands for fair competition, but where competition crosses the line into illegality we will use all legal means to protect our proprietary information and trade secrets," stated Kevin Mosher, Vice President and General Manager of Nobel Biocare's North American business.

Nobel Biocare filed its lawsuit in late 2007 claiming that Keystone Dental systematically targeted and hired Nobel Biocare's sales and marketing employees who represented a full cross-section of Nobel Biocare's business and sales force. According to Nobel Biocare's lawsuit, Keystone Dental, in an attempt to gain an unfair competitive advantage, deliberately aided and abetted those employees to breach their noncompetition and confidentiality agreements with Nobel Biocare. The lawsuit further alleged that Keystone Dental and some of its employees failed to return confidential and proprietary information belonging to Nobel Biocare and that they were unlawfully using and disclosing Nobel Biocare's information and trade secrets to develop competitive products for Keystone Dental and to induce customers to terminate their contractual or business relationships with Nobel Biocare.

Nobel Biocare's lawsuit alleged Uniform Trade Secrets Act and Connecticut's Unfair Trade Practices Act violations, unfair competition, breach of contract, civil conspiracy to commit the tort of conversion/ misappropriation, breach of fiduciary duties, breach of duty of loyalty, conversion, and tortious interference with contractual and business relations. The lawsuit sought injunctive relief and compensatory and punitive damages.

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands NobelActive(TM), Branemark System(R), NobelReplace(TM), NobelSpeedy(TM), NobelPerfect(R), NobelDirect(R), Replace Select (dental implants), Procera(R) (individualized dental prosthetics), NobelGuide(TM) (complete patient rehabilitation program) and NobelSmile(TM) (patient education and awareness program). Nobel Biocare is a full solution provider for restorative esthetic dentistry, offering a wide range of innovative Crown & Bridge & Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,500 employees and recorded revenue of EUR 665.9 million in 2007. The Company is domiciled and headquartered in Zurich, Switzerland. Production takes place at six production sites located in Sweden, the US, Japan and Israel. Nobel Biocare has 37 direct sales organizations. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange.

http://www.nobelbiocare.com


'/>"/>
SOURCE Nobel Biocare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MB Software Corporation Reaches Agreement with Keystone Equity Partners
2. Temple University Hospital, Temple University School of Medicine and Crozer-Keystone Health System Collaborate to Provide Comprehensive Kidney Care
3. Keystone Human Services Acquires Impact Systems, Inc.
4. Keystone Programs for Collaborative Discovery Launch at Fox Chase
5. Phillipsburg Easton Honda to Host Miller-Keystone Blood Drive
6. Keystone Mercy and DVCH to Offer Screenings for National Health Center Week
7. Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine
8. Delta Dental of Illinois Introduces Smile Smart For Your Health
9. Toms of Maine Tooth Floss Earns American Dental Associations Seal of Acceptance
10. Most comprehensive study of mercury in dental fillings begins
11. Guardians Dental Network Experiences Double-Digit Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Richmond, BC (PRWEB) , ... April 25, 2017 , ... ... patients from Richmond, BC, who live with dental fear and require sedation to receive ... anxiety at ease during various procedures, from hygienic cleanings to oral surgery, at ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, and ... partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable organization ... of complex spine deformity cases, particularly in children. , GSO’s focus is to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: